Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission
admin-cespu
Bibliographic reference:
Coimbra S., Oliveira H., Neuparth MJ., Proença JB., Figueiredo A., Rocha-Pereira P., & Santos-Silva A. (2016). Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. Br J Dermatol. Feb;174(2):414-6.
Coimbra S., Oliveira H., Neuparth MJ., Proença JB., Figueiredo A., Rocha-Pereira P., & Santos-Silva A. (2016). Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. Br J Dermatol. Feb;174(2):414-6.